Compare AbCellera Biologics Inc (ABCL) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Canadian National Railway Co. — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Canadian National Railway Co. trades at $122.23 (market cap $74.49B). The key difference: Canadian National Railway Co. is far larger — about 31.7× AbCellera Biologics Inc's market cap, and Canadian National Railway Co. pays a 2.1% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CNI | |
|---|---|---|
Market Cap | $2.35B | $74.49B |
Sector | Health | Industrials |
52-Week High | $8.12 | $122.78 |
52-Week Low | $2.78 | $90.91 |
Enterprise Value | $1.99B | $89.95B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
CNI trades at $122.78, up 1.0% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS in line with expectations at $1.31, following beats in prior quarters, and maintains strong profitability with a 27.23% net income margin. Recent news highlights operational records in propane and grain shipments, alongside a new rail agreement for BHP's Jansen Potash Mine, supporting long-term growth.
The outlook is positive with a consensus price target of $142.33 implying 16% upside, though high valuation multiples and rising debt levels pose risks. Analyst sentiment is mixed with 35% buy ratings, but institutional interest remains steady. Key catalysts include Q2 2026 earnings on July 24, 2026, and execution on new logistics contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
